$QURE

Meek David D. sold $54K of QURE

Meek David D. sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Meek David D.
Published Jun 12, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The disclosure updates insider ownership but does not introduce new operational or financial information about uniQure.

02

Market read

Primarily a sentiment/positioning datapoint; limited standalone trading signal without additional company catalysts.

03

What to watch

The filing does not state a 10b5-1 plan; traders may over-interpret intent—watch for follow-on insider activity or concurrent company disclosures.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure director Meek David D. filed an open-market sale of 1,993 shares at $27.06 on 2026-06-11 (Form 4).

Expected impact

Likely minimal near-term impact; any effect should be short-lived unless followed by additional insider selling or company-specific news.

Evidence & confidence

This is a Form 4 insider transaction with no 10b5-1 plan disclosed and no accompanying company event (earnings, trial, deal, or guidance).

Market effects

No clear sector read-through from a single director’s modest open-market sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for liquidity/tax and may not reflect negative views, especially when not tied to a company-specific negative event.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Meek David D.

    Director who sold 1,993 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.